Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Roles of mTOR and p-mTOR in Gastrointestinal Stromal Tumors

  • Li, Jun-Chuan (Department of Pathology, The First Affiliated Hospital of Yangtze University) ;
  • Zhu, Hong-Yu (Department of Pathology, The First Affiliated Hospital of Yangtze University) ;
  • Chen, Ting-Xuan (Department of Pathology, The First Affiliated Hospital of Yangtze University) ;
  • Zou, Lan-Ying (Department of Pathology, The First Affiliated Hospital of Yangtze University) ;
  • Wang, Xiao-Yan (Department of Pathology, The First Affiliated Hospital of Yangtze University) ;
  • Zhao, Hui-Chuan (Department of Pathology, The First Affiliated Hospital of Yangtze University) ;
  • Xu, Jun (Department of Pathology, The First Affiliated Hospital of Yangtze University)
  • Published : 2013.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study aimed to examine the relationship between expression of mammal target of rapamycin (mTOR) and phosphorylation of mTOR (p-mTOR) protein in the PI3K/Akt/mTOR signaling pathways in gastrointestinal stromal tumors and relatiuonships with clinical factors. Methods: Immunohistochemistry was used to detect the expression of the associated proteins mTOR, p-mTOR, and phosphorylation of the tumor suppressor genes PTEN, P27, VEGF, and EGFR in 40 cases of gastrointestinal stromal tumors, with division into a very low and low risk group as well as a moderate and high risk group. Results: The positive rate of mTOR and p-mTOR was significantly increased in the moderate and high risk group compared with the very low and low risk group. The difference was statistically significant (P<0.05). When grouped according to size, the positive mTOR expression rate exhibited a statistical difference (P<0.05), which was significantly increased in the group of tumors larger than 5 cm. The difference in the positive mTOR and p-mTOR expression rate exhibit no statistical significance among the PTEN, P27, VEGF, and EGFR expression subgroups (P>0.05). Conclusion: The different expressions of mTOR and p-mTOR in the signal transduction pathway of gastrointestinal stromal tumor in the different degree-of-risk groups suggested that the mTOR and p-mTOR of the signal transduction pathway serve an important function in the occurrence and development of gastrointestinal stromal tumors.

Keywords

References

  1. Al-Batran SE, Ducreux M, Ohtsu A (2012). mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer, 130, 491-6. https://doi.org/10.1002/ijc.26396
  2. Benjamin RS, Schoffski P, Hartmann JT, et al (2011). Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol, 68, 69-77. https://doi.org/10.1007/s00280-010-1431-9
  3. Carracedo A, Pandolfi PP (2008). The PTEN-PI3K pathway of feedbacks and cross-talks. Oncogene, 27, 5527-41. https://doi.org/10.1038/onc.2008.247
  4. Daniels M, Lurkin I, Pauli R, et al (2011). Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett, 312, 43-54. https://doi.org/10.1016/j.canlet.2011.07.029
  5. Eisenberg BL, Pipas JM (2012). Gastrointestinal stromal tumor-background, pathology, treatment. Hematol Oncol Clin North Am, 26, 1239-59. https://doi.org/10.1016/j.hoc.2012.08.003
  6. Foster KG, Fingar DC (2010). Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem, 285, 14071-7. https://doi.org/10.1074/jbc.R109.094003
  7. George S, Blay JY, Casali PG, et al (2009). Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer, 45, 1959-68. https://doi.org/10.1016/j.ejca.2009.02.011
  8. Gnant M (2012). Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther, 12, 1579-89. https://doi.org/10.1586/era.12.138
  9. Grabinski N, Ewald F, Hofmann BT, et a1 (2012). Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer, 11, 85. https://doi.org/10.1186/1476-4598-11-85
  10. Grover S, Ashley SW, Raut CP (2012). Small intestine gastrointestinal stromal tumors. Curr Opin Gastroenterol, 228, 113-23.
  11. Jiang J, Jin MS, Suo J, et al (2012). Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. World J Gastroenterol, 18, 2569-75. https://doi.org/10.3748/wjg.v18.i20.2569
  12. Joensuu H (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 39, 1411-9. https://doi.org/10.1016/j.humpath.2008.06.025
  13. Kee D, Zalcberg JR (2012). Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol, 4, 255-70. https://doi.org/10.1177/1758834012450935
  14. Padilla D, Menendez P, Garcia M, et al (2008). Immunohistochemical expression of epidermal growth factor and its prognostic value for gastrointestinal stromal tumors. Rev Esp Enferm Dig, 100, 752-7.
  15. Shirin H, Kravtsov V, Shahmurov M, et al (2007). The cyclin-dependent kinase inhibitor, p27, has no correlation with the malignant potential of GIST. Digestion, 75, 4-9. https://doi.org/10.1159/000101457
  16. Tamguney T, Stokoe D (2007). New insights into PTEN. J Cell Sci, 120, 4071- 9. https://doi.org/10.1242/jcs.015230
  17. Van der Meel R, Oliveira S, Altintas I, et al (2012). Tumortargeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release, 159, 281-9. https://doi.org/10.1016/j.jconrel.2011.12.027
  18. Wang CD, Huang JG, Gao X, et al (2010). Fangchinoline induced G1/S arrest by modulating expression of p27, PCNA, and cyclin D in human prostate carcinoma cancer PC3 cells and tumor xenograft. Biosci Biotech Bioch, 74, 488-93. https://doi.org/10.1271/bbb.90490
  19. Xu JL, Wang ZW, Hu LM, et al (2012). Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev, 13, 2157- 62. https://doi.org/10.7314/APJCP.2012.13.5.2157
  20. Zhang H, Bajrazewski N, Wu E, et al (2007). PDGFRs are critical for P13K/Akt activation and negatively regulated by mTOR. J CLIN INVEST, 117, 730-8. https://doi.org/10.1172/JCI28984

Cited by

  1. The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6463
  2. Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4873
  3. MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4937
  4. : review of the latest research vol.40, pp.3, 2018, https://doi.org/10.1080/08923973.2018.1441301